← Back to patent-cliff list
HYP-2090-PTSA
Tier C — Watch / tradeHYP-2090-PTSA
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KRAS G12C, Phosphatidylinositol 3-kinase
Indications (approved)：Multiple myeloma, 皮肤肿瘤, Pancreatic cancer, Endometrial cancer, Solid tumour, Non-small cell lung cancer, Colon cancer, Neoplasm
Regional status
US
-
EU
-
2025-10-01
China
Phase II
2023-12-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HYP-2090-PTSA?
Approved indications include: Multiple myeloma, 皮肤肿瘤, Pancreatic cancer, Endometrial cancer, Solid tumour, Non-small cell lung cancer, Colon cancer, Neoplasm.
When does the HYP-2090-PTSA patent expire?
No public expiry year is available for HYP-2090-PTSA yet; this page updates once verified.
How do I get a quote for HYP-2090-PTSA intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02